The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as imported into the laws of England and Wales by virtue of the European Union (Withdrawal) Act 2018 (as amended) and certain other enacting measures ("UK MAR"). With the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

24 September 2026

MicroSalt Plc

("MicroSalt" or the "Company")

Result of Subscription

MicroSalt (AIM: SALT), a leading manufacturer of full-flavour natural salt containing approximately 50% less sodium, is pleased to announce that the primary component of the Fundraising, the Subscription (as announced on 16 September 2026), was significantly over-subscribed and has now closed.

The Subscription has conditionally raised gross proceeds of approximately £1.3 million / US$1.7 million (before expenses) through the issuance of 9,213,858 Subscription Shares at 14 pence per Ordinary Share (the “Issue Price”).

On issue, each Fundraising Share (comprising the Subscription Shares, the proposed Director Subscription Shares and Retail Offer Shares) will have one warrant attached (a “Fundraising Warrant”), conditionally entitling the holder to subscribe for one new Ordinary Share in the capital of the Company (a “Warrant Share”). The allotment and issue of the Warrant Shares is conditional upon, among other things, the Company having sufficient shareholder authorities available at the time of exercise of the Fundraising Warrant or obtaining such shareholder approvals if insufficient authorities are available. The Fundraising Warrants will be exercisable for a period of three years following Admission at an exercise price of 14 pence per Warrant Share. The Fundraising Warrants will not be admitted to trading on AIM.

In addition to the Subscription, the Director Subscription is expected to raise approximately £140,000/ US$180,000, resulting in expected total gross proceeds of £1.4 million.

The Company is also providing existing Shareholders who have not participated in the Subscription or the proposed Director Subscription with the opportunity to subscribe for up to 714,285 Retail Offer Shares at the Issue Price, to raise up to £100,000 (before expenses), pursuant to a separate retail offer to be conducted via the Bookbuild Platform. Neither the Subscription nor the Director Subscription is conditional on the Retail Offer proceeding or on any minimum take-up under the Retail Offer. The Retail Offer is expected to open at 8.00 a.m. on 25 September 2026 and close at 5.00 p.m. on 29 September 2026. Further details of the Retail Offer will be set out in a separate announcement to be released shortly after this announcement.

As announced on 10 September 2026, the Ordinary Shares entered a Capital Access Window at 7.30 a.m. on that date. The Capital Access Window will cease at 2.00 p.m. on 24 September 2026, following which trading in the Ordinary Shares will resume. Admission of the 11,077,468 Conversion Shares to trading on AIM is expected to become effective, and dealings in the Conversion Shares are expected to commence, at 8.00 a.m. on 25 September 2026.

Expected timetable of the Fundraise

The expected timetable of the Fundraise has been amended as follows:

Notes:

1.         Capitalised terms used but not defined in this announcement have the meanings given to them in the Company's announcement released at 1:30pm on 16 September 2026.
2.         Unless otherwise specified, references in this Announcement to time refer to British Summer Time.

For more information, please contact:

About MicroSalt

MicroSalt is disrupting the global salt market with its patented, full-flavour, low-sodium salt designed for both food manufacturers and consumers. Using proprietary micron-sized particles, MicroSalt delivers the same salty taste as traditional salt with approximately 50% less sodium, offering a scalable solution to one of the world's most pressing health challenges.

Excess sodium consumption is a leading contributor to cardiovascular disease, the world's number one cause of death. The World Health Organisation has targeted a 30% reduction in global sodium intake by 2025, a shift projected to save seven million lives by 2030. The economic case is equally compelling: in the UK alone, cardiovascular disease costs £19 billion annually, and reducing average daily salt intake by just one gram could save over 4,000 lives and £288 million each year.